Drug Database
Back to search

Switzerland· 67230003

Mayzent 2.00 mg, Filmtabletten

A siponimod product containing siponimodum, registered in Switzerland by Novartis Pharma Schweiz AG and dispensed under Swissmedic category B, on the national reimbursement list. The same ATC class is registered in 12 of our 19 countries.

Reimbursed in Switzerland (BAG SL)Cat B (Swissmedic)ATC L04AE03

Checked against Swissmedic (Switzerland) on

Informational only — not a medical device.

SOURCE REGISTER · CHSwissmedic (Switzerland)normalisedMayzent 2.00 mg, FilmtablettenATCL04AE03REGISTER NO.67230003PACKS LISTED1CHECKEDSeptember 12, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about siponimodumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Siponimod is registered in 12 of 19 countries.

Countries holding a registration under ATC L04AE03 (siponimod), each read from that country’s own register.

  • This record: Switzerland, from Swissmedic (Switzerland)
  • 8 of them publish a price we can compare per daily dose
Search siponimod products by name

Siponimod · ATC L04AE03

12 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Italyprice
  • Netherlands
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of siponimod costs, country by country.

Normalised to the WHO defined daily dose (2 mg), so markets compare like for like.

  • Switzerland: $118.82 per daily dose (median across products in the class)
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Siponimod · price per daily dose (2 mg)

USD · FX 28 Sept 2026

  • IT Italy$120.54
  • CH Switzerland$118.82
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

Swissmedic (Switzerland)
Active substance
siponimodum
Manufacturer
Novartis Pharma Schweiz AG
Country
Switzerland (CH)
ATC code
L04AE03
ATC class
Siponimod
Defined daily dose
2 mg, O
Swissmedic category
B
Reimbursed
Yes
Source register
Swissmedic (Switzerland)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • gtin
    7680672300030
    Blist 28 Stk
    CHF 1379.6

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

667 interactions on record for siponimod.

Graded by severity as the source publishes them — 597 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check siponimod against other medicinesHow interaction checks work

Siponimod · interactions on record

667 records

  • 597 severe
  • 66 moderate
  • 4 minor

Most severe, free to view

  • CimetidineA02BA01severe
  • RanitidineA02BA02severe
  • FamotidineA02BA03severe
  • NizatidineA02BA04severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Siponimod in 11 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All siponimod products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Mayzent
  • Liechtenstein · Mayzent
  • Norway · Mayzent

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/90b3d809-9552-40c7-855f-61c254f8ad71
GET /v1/drugs/90b3d809-9552-40c7-855f-61c254f8ad71?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "unit": null,
  "strength": "siponimodum 2 mg",
  "valid_from": "2023-12-01",
  "limitations": "[{\"description\":\"Erstverschreibung durch den Facharzt für Neurologie.<br>\\nMAYZENT wird angewendet zur Behandlung von erwachsenen Patienten mit sekundär progredienter Multipler Sklerose (SPMS) mit entzündlicher Krankheitsaktivität, nachgewiesen durch klinische Schübe oder Bildgebung.<br>\\n<br>\",\"costApproval\":null,\"indication\":\"\",\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2023-12-01\"}]",
  "galenic_form": "Filmtabl 2 mg",
  "therapeutic_area": null,
  "sl_inclusion_date": "2020-12-01",
  "self_retention_pct": 10
}
API referenceMCP serverPlans

See everything about siponimod.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console